CJEU Ruling Could Prove Problematic For Gilead’s Truvada SPC
Executive Summary
A ruling by the Court of Justice of the EU has attempted to clarify the situation regarding the conditions for a supplementary protection certificate, but while it may help to settle the UK case regarding Gilead’s combination HIV drug Truvada, one practitioner says the case raises more questions than it answers.
You may also be interested in...
EU Court Advances Understanding Of SPC Patent Puzzle
Pharmaceutical companies will have a better idea of the conditions under which a supplementary protection certificate can be granted after an advocate general of the European court explained how a new legal test established last year should be used. However, lawyers caution that the opinion still leaves some aspects to be clarified.
UK Court Opens Way To Generic Versions Of Gilead’s Truvada
The High Court has ruled that Gilead’s supplementary protection certificate on Truvada is invalid, opening the way to generic versions of the combination drug for preventing HIV infection.
UK Court Opens Way To Generic Versions Of Gilead’s Truvada
The High Court has ruled that Gilead’s supplementary protection certificate on Truvada is invalid, opening the way to generic versions of the combination drug for preventing HIV infection.